(Q51317043)

3 April 2018

editorial

0 references

title

Antibody-drug conjugates: present and future. (English)

1 reference

3 April 2018

1 reference

2

1 reference

3 April 2018

author name string

Alain Beck

series ordinal

1

1 reference

3 April 2018

publication date

1 January 2014

1 reference

3 April 2018

published in

Monoclonal Antibodies

1 reference

3 April 2018

volume

6

1 reference

3 April 2018

issue

1

1 reference

3 April 2018

page(s)

15-17

1 reference

3 April 2018

Strategies and challenges for the next generation of therapeutic antibodies

cites work

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

Site-specific antibody drug conjugates for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

Analytical methods for physicochemical characterization of antibody drug conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

Characterization of therapeutic antibodies and related products.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.27436

Antibodies to watch in 2014.

21 January 2018

1 reference

12 December 2020

Methods for site-specific drug conjugation to antibodies

1 reference

12 December 2020

Antibody-drug conjugate model fast characterization by LC-MS following IdeS proteolytic digestion

1 reference

12 December 2020

The next generation of antibody-drug conjugates comes of age.

1 reference

12 December 2020

Identifiers

DOI

10.4161/MABS.27436

1 reference

3 April 2018

PMC publication ID

7098595

0 references

1 reference

3 April 2018